Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis

Yuta Takahashi, Kazuhiko Shien, Shuta Tomida, Shinsuke Oda, Takehiro Matsubara, Hiroki Sato, Ken Suzawa, Eisuke Kurihara, Yusuke Ogoshi, Kei Namba, Takahiro Yoshioka, Hidejiro Torigoe, Hiromasa Yamamoto, Junichi Sou, Shinichi Toyooka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In patients presenting with synchronous or metachronous multiple lung cancer (MLC), it is important to distinguish between multiple primary lung cancer (MP) and intrapulmonary metastasis (IM). The present study was aimed at investigating the mutational profiles of synchronous/metachronous MLC and to compare the classification of paired tumors by multiplex gene mutation analysis with the histopathological evaluation. We carried out targeted sequencing of 20 lung cancer-related oncogenes using next-generation sequencing (NGS) in 82 tumors from 37 MLC patients who underwent surgical resection at our department. The patients were diagnosed as MP or IM cases based on the Martini and Melamed criteria, histopathological and gene mutational evaluations. Matching mutations between paired tumors was observed in 20 (54%) patients, who were diagnosed as IM cases by mutational evaluation. Patients who could not be clearly diagnosed by histopathological evaluation were classified as equivocal cases. Among the histopathological IM cases (n = 7), six (86%) were confirmed as IM cases also by mutational evaluation, and most of the paired tumors of these cases (n = 5) harbored multiple matching mutations. Among the histopathological MP cases (n = 17), mutational evaluation yielded a discordant diagnosis in eight (47%) cases. Of these, the paired tumors of four cases harbored multiple matching mutations, suggesting that the mutational diagnosis might be more suitable in these patients. Our findings suggest that multiplex mutational analysis could be a useful complementary tool for distinguishing between MP and IM in addition to histopathological evaluation.

Original languageEnglish
JournalCancer Science
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Oncogenes
Lung Neoplasms
Mutation
Neoplasm Metastasis
Neoplasms
Genes

Keywords

  • classification
  • clonality
  • gene mutation
  • multiple lung cancer
  • next-generation sequencing

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis. / Takahashi, Yuta; Shien, Kazuhiko; Tomida, Shuta; Oda, Shinsuke; Matsubara, Takehiro; Sato, Hiroki; Suzawa, Ken; Kurihara, Eisuke; Ogoshi, Yusuke; Namba, Kei; Yoshioka, Takahiro; Torigoe, Hidejiro; Yamamoto, Hiromasa; Sou, Junichi; Toyooka, Shinichi.

In: Cancer Science, 01.01.2018.

Research output: Contribution to journalArticle

Takahashi, Y, Shien, K, Tomida, S, Oda, S, Matsubara, T, Sato, H, Suzawa, K, Kurihara, E, Ogoshi, Y, Namba, K, Yoshioka, T, Torigoe, H, Yamamoto, H, Sou, J & Toyooka, S 2018, 'Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis', Cancer Science. https://doi.org/10.1111/cas.13797
Takahashi, Yuta ; Shien, Kazuhiko ; Tomida, Shuta ; Oda, Shinsuke ; Matsubara, Takehiro ; Sato, Hiroki ; Suzawa, Ken ; Kurihara, Eisuke ; Ogoshi, Yusuke ; Namba, Kei ; Yoshioka, Takahiro ; Torigoe, Hidejiro ; Yamamoto, Hiromasa ; Sou, Junichi ; Toyooka, Shinichi. / Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis. In: Cancer Science. 2018.
@article{84961adbbbda4d2c9bd56f35f0ad490d,
title = "Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis",
abstract = "In patients presenting with synchronous or metachronous multiple lung cancer (MLC), it is important to distinguish between multiple primary lung cancer (MP) and intrapulmonary metastasis (IM). The present study was aimed at investigating the mutational profiles of synchronous/metachronous MLC and to compare the classification of paired tumors by multiplex gene mutation analysis with the histopathological evaluation. We carried out targeted sequencing of 20 lung cancer-related oncogenes using next-generation sequencing (NGS) in 82 tumors from 37 MLC patients who underwent surgical resection at our department. The patients were diagnosed as MP or IM cases based on the Martini and Melamed criteria, histopathological and gene mutational evaluations. Matching mutations between paired tumors was observed in 20 (54{\%}) patients, who were diagnosed as IM cases by mutational evaluation. Patients who could not be clearly diagnosed by histopathological evaluation were classified as equivocal cases. Among the histopathological IM cases (n = 7), six (86{\%}) were confirmed as IM cases also by mutational evaluation, and most of the paired tumors of these cases (n = 5) harbored multiple matching mutations. Among the histopathological MP cases (n = 17), mutational evaluation yielded a discordant diagnosis in eight (47{\%}) cases. Of these, the paired tumors of four cases harbored multiple matching mutations, suggesting that the mutational diagnosis might be more suitable in these patients. Our findings suggest that multiplex mutational analysis could be a useful complementary tool for distinguishing between MP and IM in addition to histopathological evaluation.",
keywords = "classification, clonality, gene mutation, multiple lung cancer, next-generation sequencing",
author = "Yuta Takahashi and Kazuhiko Shien and Shuta Tomida and Shinsuke Oda and Takehiro Matsubara and Hiroki Sato and Ken Suzawa and Eisuke Kurihara and Yusuke Ogoshi and Kei Namba and Takahiro Yoshioka and Hidejiro Torigoe and Hiromasa Yamamoto and Junichi Sou and Shinichi Toyooka",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/cas.13797",
language = "English",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis

AU - Takahashi, Yuta

AU - Shien, Kazuhiko

AU - Tomida, Shuta

AU - Oda, Shinsuke

AU - Matsubara, Takehiro

AU - Sato, Hiroki

AU - Suzawa, Ken

AU - Kurihara, Eisuke

AU - Ogoshi, Yusuke

AU - Namba, Kei

AU - Yoshioka, Takahiro

AU - Torigoe, Hidejiro

AU - Yamamoto, Hiromasa

AU - Sou, Junichi

AU - Toyooka, Shinichi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In patients presenting with synchronous or metachronous multiple lung cancer (MLC), it is important to distinguish between multiple primary lung cancer (MP) and intrapulmonary metastasis (IM). The present study was aimed at investigating the mutational profiles of synchronous/metachronous MLC and to compare the classification of paired tumors by multiplex gene mutation analysis with the histopathological evaluation. We carried out targeted sequencing of 20 lung cancer-related oncogenes using next-generation sequencing (NGS) in 82 tumors from 37 MLC patients who underwent surgical resection at our department. The patients were diagnosed as MP or IM cases based on the Martini and Melamed criteria, histopathological and gene mutational evaluations. Matching mutations between paired tumors was observed in 20 (54%) patients, who were diagnosed as IM cases by mutational evaluation. Patients who could not be clearly diagnosed by histopathological evaluation were classified as equivocal cases. Among the histopathological IM cases (n = 7), six (86%) were confirmed as IM cases also by mutational evaluation, and most of the paired tumors of these cases (n = 5) harbored multiple matching mutations. Among the histopathological MP cases (n = 17), mutational evaluation yielded a discordant diagnosis in eight (47%) cases. Of these, the paired tumors of four cases harbored multiple matching mutations, suggesting that the mutational diagnosis might be more suitable in these patients. Our findings suggest that multiplex mutational analysis could be a useful complementary tool for distinguishing between MP and IM in addition to histopathological evaluation.

AB - In patients presenting with synchronous or metachronous multiple lung cancer (MLC), it is important to distinguish between multiple primary lung cancer (MP) and intrapulmonary metastasis (IM). The present study was aimed at investigating the mutational profiles of synchronous/metachronous MLC and to compare the classification of paired tumors by multiplex gene mutation analysis with the histopathological evaluation. We carried out targeted sequencing of 20 lung cancer-related oncogenes using next-generation sequencing (NGS) in 82 tumors from 37 MLC patients who underwent surgical resection at our department. The patients were diagnosed as MP or IM cases based on the Martini and Melamed criteria, histopathological and gene mutational evaluations. Matching mutations between paired tumors was observed in 20 (54%) patients, who were diagnosed as IM cases by mutational evaluation. Patients who could not be clearly diagnosed by histopathological evaluation were classified as equivocal cases. Among the histopathological IM cases (n = 7), six (86%) were confirmed as IM cases also by mutational evaluation, and most of the paired tumors of these cases (n = 5) harbored multiple matching mutations. Among the histopathological MP cases (n = 17), mutational evaluation yielded a discordant diagnosis in eight (47%) cases. Of these, the paired tumors of four cases harbored multiple matching mutations, suggesting that the mutational diagnosis might be more suitable in these patients. Our findings suggest that multiplex mutational analysis could be a useful complementary tool for distinguishing between MP and IM in addition to histopathological evaluation.

KW - classification

KW - clonality

KW - gene mutation

KW - multiple lung cancer

KW - next-generation sequencing

UR - http://www.scopus.com/inward/record.url?scp=85054541551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054541551&partnerID=8YFLogxK

U2 - 10.1111/cas.13797

DO - 10.1111/cas.13797

M3 - Article

C2 - 30216592

AN - SCOPUS:85054541551

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

ER -